New European research project aims to tackle antibiotic resistance issue raised by WHO via inhalable nanotherapeutics
About Ingeniatrics
Monday, 07 July 2014 11:00





A new research project (PneumoNP) is aimed at tackling antibiotic resistance in respiratory tract infections via the use of inhalable nanotherapeutic compounds. Funded under the FP7 programme by the European Commission, the 4-year long PneumoNP project brings together top research institutes, universities, clinicians and enterprises from 6 EU member states. This novel collaboration will contribute to answer the call of the World Health Organization (WHO), who recently released an alarming report on the global threat of antibiotic resistance. The project will develop an innovative solution to antibiotic resistance by coupling new antibiotics to inhalable carrier molecules, resulting in more efficient targeting of antibiotics to infection-causing bacteria present in the respiratory tract.

For more information, click here



 
The most perfect microcapsules of the world
About Ingeniatrics
Wednesday, 16 April 2014 10:00

El Mundo, the Spanish newspaper in their online edition collect an interesting interview with Agustín Mariscal, CEO of Ingeniatrics in the Innovation section.

The article gives an overview on the main technologies patented by the company, Flow Focusing® and Flow Blurring® which are critical to product development in several fields such as pharma, food or consumer goods.

If you want to know more about Ingeniatrics’ competitive advantages, countries to which exports or industries in which operates, read the full story here

 
Ingeniatrics, partner of the 7th European Framework programme PneumoNP project, participates in the Kick off Meeting in San Sebastian, Spain on 28th 29th January 2014
About Ingeniatrics
Wednesday, 29 January 2014 14:00

PneumoNP’s 11 partners from 6 EU member states meet in San Sebastian, Spain on 28th/29th January 2014. PneumoNP is a European large research project funded under the Seventh Framework Programme (2014-2017) with a budget more than 5.5 M€.

Aiming to diagnose and treat antibiotic resistant pneumonia infections. Each partner has a distinctive role in the project, and brings its own expertise to the group. Ingeniatrics will be responsible for the creation of an optimal aerosol with the previous developed drug formulation with a defined droplet size and size distribution. Ingeniatrics know how in Drug Delivery and microencapsulation of high sensitive active pharmaceutical ingredients(API’s) will be beneficial for the whole development.

The main objective of the project is the development of a therapy and a diagnosis system for the treatment of lung infection (pneumonia). According to most of the international stakeholders from the healthcare sector, resistant Gram-negative bacteria are one of the major global health issues due to unavailable effective treatments. The PneumoNP team will focus its attention on infections caused by Klebsiella pneumoniae.

The application of nanotechnology to medicine always raises concerns among citizens, with good reasons. The incorporation of nanomaterials into the human body sometimes is a subject of reluctance. In PneumoNP all the existing safety and risk assessments will be strictly followed, especially all the recommendations generated by the European Commission. Dialogue about nanomedicine will be initiated with involved citizens (press relations, website, twitter…) through its dissemination activities. Finally, the project aims at showing that nanotherapy based drugs will reduce side effects, produce safer treatments and enable the use of biomolecule based drugs.

Furthermore PneumoNP will develop a new theragnostic system for a rapid identification of the bacteria strain causing the infection, and targeted treatment of the infected area with a selective therapeutic nanosystem.


This project has received funding from the European Union’s Seventh Programme for research, technological development and demonstration under grant agreement No 604434


 
 
Ingeniatrics develops tailor-made nebulizer
About Ingeniatrics
Monday, 06 January 2014 14:00
There are no translations available.

alt
 

Ingeniatrics está especializada en el manejo de fluidos, el diseño y la fabricación de nebulizadores utilizados en multitud de áreas.

Son nebulizadores muy valorados en el análisis químico del agua (agua de mar, residuos, procesos, etc.) y otras sustancias por ICP -OES y MP -AES (OneNeb®). Además se utilizan en el tratamiento de agua residual (lixiviados, encurtidos, etc.), refrigeración evaporativa, humidificación y la microencapsulación de microorganismos (Cellena®). Estos nebulizadores son únicos debido a sus tecnologías pantentadas: Flow Focusing® y Flow Blurring®.

Se han desarrollado varios prototipos para la creación de gotas con diámetro inferior a 5 micras. Estos son para una aplicación única que requiere un flujo continuo de gotitas nebulizadas de una química especial que afecta el proceso final. Se han probado otros nebulizadores para estas aplicaciones concretas pero ninguno de ellos ofrece la posibilidad de dosificar la química en un tamaño de partícula muy pequeño en el aire.


Otro prototipo fue desarrollado para la producción de partículas entre 0,8 y 1 mm utilizando suspensiones oleosas viscosas consiguiendo tasas de flujo de líquido en 200Kg por hora. Las partículas son generadas con la tecnología Flow Blurring® en combinación con las fuerzas electro-hidrodinámicas. Cada prototipo se entrega con los informes de control de calidad y una guía de usuario para asegurar la correcta gestión de los operadores finales.


Ingeniatrics está formado por profesionales con experiencia en investigación e ingeniería, dirigido por un equipo gerencial que se identifica y se ha comprometido con los objetivos estratégicos de la compañía, misión y valores.
 
 
Evonik´s 1st International Symposium on Solubility Enhancement
About Ingeniatrics
Tuesday, 29 October 2013 14:32

Evonik, Ingeniatrics´  business partner and one of the world's leading specialty chemicals companies with three reporting segments: Consumer, Health & Nutrition and Resource Efficiency and Specialty Materials, is holding the 1st International Symposium on Solubility Enhancement, taking place in Frankfurt, Germany.

This seminar will be an excellent opportunity  for lab managers and senior scientists from formulation development, scale-up, production or process development who have specific interest in solubility enhancement with EUDRAGIT® polymers and want to learn more about spray drying and melt extrusion.

María Flores, Ingeniatrics R&D Director, will be in the symposium as a guest speaker and industry expert, given a talk on the subject: “A novel convenient technology to generate core-shell particles”.

For more information and inscriptions, please follow the link:

http://eudragit.evonik.com/sites/dc/Downloadcenter/Evonik/Product/EUDRAGIT/Workshops/invitation---1st-international-symposium-on-solubility-enhancement.pdf

 
VII Forum on Industrial Applications of Nanotechnology (AIN)
About Ingeniatrics
Wednesday, 09 October 2013 12:15

Dr. Agustín Mariscal, Ingeniatrics´ CEO and Miriam Goldberg, Key Account Manager

The VII Forum on Industrial Applications of Nanotechnology, attended by companies specialize in Nanobiomedicine, Nanotechnology, Nanomaterials, Nanoscience , Biotechnology , Chemical, Consumer Goods Industry etc . , took place on October 1st, 2013, in La Casa Llotja de Mar , Barcelona , and was hold by the University Institute of Nanoscience of Aragon (INA ) .

Ingeniatrics was invited, as company expert in nano and microtechnology, to participate in one of the two round tables that took place that day, that one in Nanomedicine and Nanotechnology.


The forum discussion covered topics such as initial barriers found by research entities in order to transfer their technology to the industrial sector; facing the technology transfer stage, while protecting their patents and know-how; industry adaptation to be successful, given that it must adapt its facilities, equipment, working ways, etc.;  manufacture of biotechnology products and registration requirements in the pharmaceutical sector; current regulatory laws in Europe and in the United States, as an obstacle to the development of new products in nanomedicine , even having shown significant therapeutic efficacy;  difficulties that arise during scale production;  and personal experiences of the participating companies.

In the picture, from left to right, Dr. Scott Mitchell (BioNANOSurf), David Galán (FLUIDNATEK), Carlos Lurigados Delgado (BIOCAT), Dr. Agustín Mariscal (Ingeniatrics), Miriam Goldberg (Ingeniatrics) and Dr. Oscar P. Gulin (Argon Pharma).

 

 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 1 of 20